Tavilermide

N/A

Report date: 2026/03/09 20:02:04
NME

Base Information

Drug NameTavilermide
Drug Alias Nametavilermida他维乐肽他维勒胺tavilermidumtavilermide +[7] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionBeta-nerve growth factor stimulantsNerve growth factor receptor Trk-A activators
TargetsBeta-nerve growth factorNerve growth factor receptor Trk-A
Therapy Area/IndicationsDry Eye SyndromesXerophthalmiaKeratoconjunctivitis Sicca
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesMimetogen Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesAllergan PlcMimetogen Pharmaceuticals Usa Inc
Inactive CompaniesN/A
Active IndicationsDry Eye SyndromesKeratoconjunctivitis Sicca
Inactive IndicationsXerophthalmia

Other Information

ATC CodeN/A
Related LinksWikipedia